MedTrace Logo

Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients

NCT01779401 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1078

Last updated 2017-07-19

No results posted yet for this study

Summary

To identify the high-risk patients who might have in-stent thrombosis after PCI with thromboelastography and to head-to-head compare two intensified antiplatelet therapeutic strategies of double-dosage Clopidogrel and triple antiplatelet therapy with Cilostazol with the standard antiplatelet therapy.

Conditions

Interventions

DRUG

Clopidogrel 75mg

DRUG

Clopidogrel 150mg

DRUG

Aspirin 100mg

DRUG

Cilostazol 100mg

Sponsors & Collaborators

  • Beijing Municipal Health Bureau

    collaborator OTHER

  • Haemonetics Corporation

    collaborator INDUSTRY

  • Zhejiang Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    lead OTHER

Principal Investigators

  • Yuejin Yang, PHD · Chinese Academy of Medical Sciences, Fuwai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01779401 on ClinicalTrials.gov